ESR1 and breast carcinoma: Considering that our SC31 model was partly suppressed by endocrine therapy in our previous study,15 we speculate that the IFN‐responsive signalling would be usually suppressed by oestrogen in ER+ breast cancers, but once the oestrogen signalling was inhibited, the IFN‐responsive population would become dominant for the breast cancer's progression.